<?xml version="1.0" encoding="UTF-8"?>
<ref id="B97-pharmaceuticals-12-00157">
 <label>97.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wilder-Smith</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Vannice</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Durbin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Hombach</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Thomas</surname>
    <given-names>S.J.</given-names>
   </name>
   <name>
    <surname>Thevarjan</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Simmons</surname>
    <given-names>C.P.</given-names>
   </name>
  </person-group>
  <article-title>Zika vaccines and therapeutics: Landscape analysis and challenges ahead</article-title>
  <source>BMC Med.</source>
  <year>2018</year>
  <volume>16</volume>
  <elocation-id>84</elocation-id>
  <pub-id pub-id-type="doi">10.1186/s12916-018-1067-x</pub-id>
  <?supplied-pmid 29871628?>
  <pub-id pub-id-type="pmid">29871628</pub-id>
 </element-citation>
</ref>
